Cantor Fitzgerald Forecasts AARD FY2024 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Aardvark Therapeutics in a note issued to investors on Monday, March 10th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($3.89) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Aardvark Therapeutics’ FY2025 earnings at ($2.49) EPS.

Several other equities research analysts also recently commented on the company. Royal Bank of Canada began coverage on Aardvark Therapeutics in a report on Monday. They issued an “outperform” rating and a $21.00 target price on the stock. Morgan Stanley assumed coverage on Aardvark Therapeutics in a report on Monday. They issued an “overweight” rating and a $29.00 target price on the stock. Finally, Bank of America assumed coverage on Aardvark Therapeutics in a report on Monday. They set a “buy” rating and a $22.00 price target on the stock.

Aardvark Therapeutics Trading Up 1.6 %

Aardvark Therapeutics stock opened at $10.42 on Wednesday. Aardvark Therapeutics has a 12 month low of $9.21 and a 12 month high of $19.58.

Insider Activity at Aardvark Therapeutics

In other news, CFO Nelson Sun acquired 10,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the transaction, the chief financial officer now owns 99,484 shares in the company, valued at $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Tien-Li Lee acquired 16,542 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, with a total value of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares of the company’s stock, valued at $23,938,800. The trade was a 1.12 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.